Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.

Potter V, Moore J.

Rev Recent Clin Trials. 2008 May;3(2):130-8. Review.

PMID:
18474024
2.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
5.

Acute graft-vs-host disease: pathobiology and management.

Goker H, Haznedaroglu IC, Chao NJ.

Exp Hematol. 2001 Mar;29(3):259-77. Review. Erratum in: Exp Hematol 2001 May;29(5):653.

PMID:
11274753
6.

[Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].

Graf Finckenstein F, Zabelina T, Dürken M, Dahlke J, Kröger N, Krüger W, Janka-Schaub G, Erttmann R, Zander AR, Kabisch H.

Klin Padiatr. 2002 Jul-Aug;214(4):206-11. German.

PMID:
12165903
8.

Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.

Ziakas PD, Zervou FN, Zacharioudakis IM, Mylonakis E.

PLoS One. 2014 Dec 8;9(12):e114735. doi: 10.1371/journal.pone.0114735. eCollection 2014.

9.

Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.

Auletta JJ, Cooke KR.

Curr Opin Pediatr. 2009 Feb;21(1):30-8. doi: 10.1097/MOP.0b013e3283207b2f. Review.

PMID:
19242239
11.

Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.

Quellmann S, Schwarzer G, Hübel K, Greb A, Engert A, Bohlius J.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004885. doi: 10.1002/14651858.CD004885.pub2. Review.

PMID:
18646116
12.

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.

Maloney DG.

Leuk Lymphoma. 2003;44 Suppl 3:S99-105. Review.

PMID:
15202532
13.

Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.

Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, Bashey A.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1828-34. doi: 10.1016/j.bbmt.2014.07.020. Epub 2014 Jul 23.

14.

Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.

Krstevska S, Genadieva-Stavric S, Pivkova A, Stojanovski Z, Georgievski B, Balkanov T.

Med Arh. 2011;65(5):260-4.

PMID:
22073847
15.

Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.

Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10.

16.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28.

17.

Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.

Yan CH, Xu LP, Liu DH, Chen H, Wang Y, Wang JZ, Wang FR, Han W, Liu KY, Huang XJ.

Clin Transplant. 2015 Jul;29(7):594-605. doi: 10.1111/ctr.12561. Epub 2015 Jun 13.

PMID:
25969866
18.
19.

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH.

J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10.

20.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.

Supplemental Content

Support Center